GRI Reference Table
Global Reporting Frameworks
Pfizer continues to evaluate our approach to non-financial reporting, including reference to several existing, globally recognized external frameworks.
These include the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB) and the International Integrated Reporting Council (IIRC). We have relied on elements of each framework in developing this year's Annual Review while adhering to none in its entirety. We have included a GRI Reference Table in this Annual Review as a reference tool to help readers more readily locate relevant information across Pfizer's web-based resources.
We also take into account elements of other Environment, Social and Governance (ESG) indices and sustainability indicators, in particular the Access to Medicines Index and the United Nations (UN) Sustainable Development Goals (SDGs).
Download GRI Reference Table
GRI Indicator | Description | Reference | Alignment with the SDGs* |
---|---|---|---|
GRI 102: General Disclosures 2017 Organizational Profile |
|||
102-1 | Name of the organization | Pfizer Inc. | |
102-2 | Activities, brands, products, and services | CEO Letter | |
102-3 | Location of headquarters | New York, New York (U.S.) | |
102-4 | Location of operations | Delivering Value through our Global Businesses | |
102-5 | Ownership and legal form | Corporate and Shareholder Information | |
102-6 | Markets served | Delivering Value through our Global Businesses | |
102-7 | Scale of the organization | CEO Letter | |
102-9 | Supply chain | Manufacturing and Supply Chain Excellence | Goal Goal |
102-11 | Precautionary Principle or approach | Pfizer manages and reports on our risks and impacts in consideration of the precautionary principle. | |
102-12 | External initiatives | Governance and Ethics | |
102-13 | Membership of associations | Lobbying and Political Contributions | |
Strategy | |||
102-14 | Statement from senior decision-maker | CEO Letter | |
102-15 | Key impacts, risks, and opportunities | Governance and Ethics | |
Ethics and Integrity | |||
102-16 | Values, principles, standards, and norms of behavior | Pfizer Compliance | Goal |
102-17 | Mechanisms for advice and concerns about ethics | Governance and Ethics | |
Governance | |||
102-18 | Governance structure | Governance and Ethics | |
102-19 | Delegating authority | Corporate Governance FAQs | |
102-20 | Executive-level responsibility for economic, environmental and social topics | Environment, Health & Safety | Goal |
102-21 | Consulting stakeholders on economic, environmental and social topics | Stakeholder Engagement | |
102-22 | Composition of the highest governance body and its committees | Board of Directors | Goal |
102-23 | Chair of the highest governance body | The Pfizer Board: Board Policies | Goal |
102-24 | Nominating and selecting the highest governance body | The Pfizer Board: Board Policies | Goal Goal |
102-25 | Conflicts of interest | The Pfizer Board: Board Policies | Goal |
102-26 | Role of highest governance body in setting purpose, values, and strategy | The Pfizer Board: Board Policies | |
102-27 | Collective knowledge of highest governance body | Board Committees and Charters | |
102-28 | Evaluating the highest governance body's performance | Board Committees and Charters | |
102-29 | Identifying and managing economic, environmental and social impacts | The Pfizer Board: Board Policies Board Committees and Charters |
Goal |
102-31 | Review of economic, environmental and social topics | The Pfizer Board: Board Policies Board Committees and Charters |
|
102-32 | Highest governance body's role in sustainability reporting | About this Review Board Committees and Charters |
|
Stakeholder Engagement | |||
102-40 | List of stakeholder groups | Stakeholder Engagement | |
102-43 | Approach to stakeholder engagement | Stakeholder Engagement | |
Reporting practice | |||
102-45 | Entities included in the consolidated financial statements | About this Review | |
102-46 | Defining report content and topic Boundaries | About this Review | |
102-47 | List of material topics | About this Review | |
102-49 | Changes in reporting | No changes in reporting since 2016 report | |
102-50 | Reporting period | About this Review | |
102-51 | Date of most recent report | March 12, 2018 | |
102-52 | Reporting cycle | We report on an annual basis | |
102-53 | Contact point for questions regarding the report | Chris Gray, Senior Director, Corporate Responsibility | |
102-55 | GRI content index | GRI Reference Table | |
Material topics Economic GRI 103: Management Approach 2017 |
|||
103-1 | Explanation of the material topic and its Boundary | About this Review | |
103-2 | The management approach and its components | Product Stewardship | |
103-3 | Evaluation of the management approach | Product Stewardship | |
Economic Performance | |||
201-1 | Direct economic value generated and distributed | Performance | |
Indirect Economic Impacts | |||
203-1 | Infrastructure investments and services supported | Individual Voices | |
203-2 | Significant indirect economic impacts | Understanding the External Environment Manufacturing & Supply Chain Excellence Community Health Access to Medicines Anti-Infectives |
Goal Goal Goal Goal |
Procurement Practices | |||
204-1 | Proportion of spending on local suppliers | Ethics and Compliance | Goal |
Anti-corruption | |||
205-1 | Operations assessed for risks related to corruption | Pfizer Compliance | Goal |
Environmental Water |
|||
303-1 | Water withdrawal by source | Performance | Goal |
Emissions | |||
305-1 | Direct (Scope 1) GHG emissions | Performance Environment, Health & Safety Environmental KPIs |
Goal |
305-2 | Energy indirect (Scope 2) GHG emissions | Performance Environment, Health & Safety Environmental KPIs |
Goal |
Effluents and Waste | |||
306-2 | Waste by type and disposal method | Performance | Goal |
Supplier Environmental Assessment | |||
308-2 | Negative environmental impacts in the supply chain and actions taken | Performance | Goal |
Social Occupational Health & Safety |
|||
403-2 | Types of injury and rates of injury, occupational diseases, lost days, and absenteeism and number of work-related fatalities | Environment, Health & Safety Performance |
Goal Goal |
Training and Education | |||
404-1 | Average hours of training per year per employee | Culture | Goal Goal Goal |
404-2 | Programs for upgrading employee skills and transition assistance programs | Culture | Goal |
Non-discrimination | |||
406-1 | Incidents of discrimination and corrective actions taken | Culture |
Goal Goal Goal |
Human Rights Assessment | |||
412-2 | Employee training on human rights policies or procedures | Human Rights Statement | |
Local Communities | |||
413-1 | Operations with local community engagement, impact assessments and development programs | Community Health | Goal Goal Goal Goal Goal Goal |
Public Policy | |||
415-1 | Political contributions | Corporate and Shareholder Information | Goal |
Customer Privacy | |||
418-1 | Substantiated complaints concerning breaches of customer privacy and losses of customer data | How We Conduct Clinical Trials | Goal |
* Based on ‘SDG Compass: Linking the SDGs and GRI’, as available on the GRI website’s resource library. Click here to view.